TY - JOUR
T1 - Magnoflorine from Tinospora crispa upregulates innate and adaptive immune responses in Balb/c mice
AU - Ahmad, Waqas
AU - Jantan, Ibrahim
AU - Haque, Md Areeful
AU - Arsyad, Laiba
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/10
Y1 - 2022/10
N2 - Magnoflorine shows a diverse range of pharmacological actions, including immunomodulatory, antioxidant and neuropharmacological activities. However, its effects on the immune responses in animal studies have not been reported. In this study, magnoflorine isolated from Tinospora crispa, at doses of 25, 50 and 100 mg/kg was administered to male Balb/c mice daily for 14 days to evaluate its effect on innate immune responses, while for evaluation of adaptive immune responses, on day 0 the mice were injected intraperitoneally with sheep red blood cells (sRBC) and treated orally with the various doses of magnoflorine for the same duration. The effects of magnoflorine on phagocytosis, myeloperoxidase (MPO) activity, lysozyme serum level, nitric oxide (NO) production, CD4+ and CD8+ cells population, T and B lymphocytes proliferation, activated T cells cytokines production, antibodies levels and delayed type hypersensitivity (DTH) were determined. Magnoflorine dose-dependently stimulated NO production, E. coli engulfment by neutrophils and peritoneal macrophages, MPO activity and lysozyme serum level in treated mice. Magnoflorine at 100 mg/kg exhibited comparable stimulation of B cell production compared to levamisole at 2.5 mg/kg. It also significantly increased CD4+ and CD8+ cells population, upregulated the Th1 (IFN-γ, IL-2 and TNF-α) and Th2 (IL-4 and IL-6) cytokines in a dose-dependent manner. At similar concentrations, magnoflorine also exhibited a strong dose-dependent stimulation on DTH reaction and upregulation of immunoglobulins (IgG and IgM) production in mice immunized with sRBC. The strong upregulation of innate and adaptive immune responses indicates that magnoflorine has potential to be developed into an effective immunostimulant.
AB - Magnoflorine shows a diverse range of pharmacological actions, including immunomodulatory, antioxidant and neuropharmacological activities. However, its effects on the immune responses in animal studies have not been reported. In this study, magnoflorine isolated from Tinospora crispa, at doses of 25, 50 and 100 mg/kg was administered to male Balb/c mice daily for 14 days to evaluate its effect on innate immune responses, while for evaluation of adaptive immune responses, on day 0 the mice were injected intraperitoneally with sheep red blood cells (sRBC) and treated orally with the various doses of magnoflorine for the same duration. The effects of magnoflorine on phagocytosis, myeloperoxidase (MPO) activity, lysozyme serum level, nitric oxide (NO) production, CD4+ and CD8+ cells population, T and B lymphocytes proliferation, activated T cells cytokines production, antibodies levels and delayed type hypersensitivity (DTH) were determined. Magnoflorine dose-dependently stimulated NO production, E. coli engulfment by neutrophils and peritoneal macrophages, MPO activity and lysozyme serum level in treated mice. Magnoflorine at 100 mg/kg exhibited comparable stimulation of B cell production compared to levamisole at 2.5 mg/kg. It also significantly increased CD4+ and CD8+ cells population, upregulated the Th1 (IFN-γ, IL-2 and TNF-α) and Th2 (IL-4 and IL-6) cytokines in a dose-dependent manner. At similar concentrations, magnoflorine also exhibited a strong dose-dependent stimulation on DTH reaction and upregulation of immunoglobulins (IgG and IgM) production in mice immunized with sRBC. The strong upregulation of innate and adaptive immune responses indicates that magnoflorine has potential to be developed into an effective immunostimulant.
KW - Immune responses
KW - Immunoglobulins
KW - Immunostimulant
KW - Magnoflorine
KW - Phagocytosis
KW - Tinospora crispa
UR - http://www.scopus.com/inward/record.url?scp=85135044259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135044259&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2022.109081
DO - 10.1016/j.intimp.2022.109081
M3 - Article
C2 - 35907339
AN - SCOPUS:85135044259
SN - 1567-5769
VL - 111
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 109081
ER -